Plasma Fractionation Market Size & Share, by Product {Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin}; Application (Immunology, Hematology, Critical Care, Rheumatology, Neurology); End-user (Hospitals, Clinical Research Lab, Academic Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4548
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Companies Dominating the Plasma Fractionation Landscape

top-features-companies
    • CSL Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Grifols, S.A.
    • Takeda Pharmaceutical Company Limited
    • Kedrion S.p.A
    • Octapharma AG
    • Bio Products Laboratory Ltd.
    • Biotest AG
    • LFB Group
    • Japan Blood Products Organization
    • Intas Pharmaceuticals Ltd. 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Grifols, S.A., a global healthcare company and one of the world's leading producers of plasma-derived medicines, announced the acquisition of its first donation center in Canada as part of the company's commitment to increasing access to lifesaving plasma medications in the country.

  • The Czech health authority SUKL has granted Biotest AG the operating license for the 12th Cara Plasma plasmapheresis center in the Czech Republic.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4548
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are increase In number of chronic diseases, growing geriatric population, increased investment by major players, and others.

The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2033.

High cost related to plasma therapy, increasing use of recombinant alternatives, and restricted medical reimbursement policies are some of the major factors expected to hinder the growth of the market.

The market in Europe is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, Kedrion S.p.A and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, application, end-user, and by region.

The neurology segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying